PROKIDNEY CP (PROK)
(Delayed Data from NSDQ)
$1.83 USD
+0.21 (12.96%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.82 -0.01 (-0.55%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PROK 1.83 +0.21(12.96%)
Will PROK be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for PROK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROK
Play Likely Earnings Beat With 3 Top-Ranked Stocks
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
PROK: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
Other News for PROK
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
Maintaining Hold on ProKidney: Balancing Potential Against Need for Further Efficacy Data
ProKidney initiated with neutral view at JPMorgan, here's why
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Tesla deliveries, Nike earnings, port strike threat and the jobs report